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Abstract: Oxidative stress is a well-described imbalance between the production of reactive oxygen
species (ROS) and the antioxidant defense system of cells and tissues. The overproduction of free
radicals damages all components of the cell (proteins, lipids, nucleic acids) and modifies their
physiological functions. As widely described, this condition is a biochemical hallmark of chronic
kidney disease (CKD) and may dramatically influence the progression of renal impairment and the
onset/development of major systemic comorbidities including cardiovascular diseases. This state
is exacerbated by exposure of the body to uremic toxins and dialysis, a treatment that, although
necessary to ensure patients’ survival, exposes cells to non-physiological contact with extracorporeal
circuits and membranes with consequent mitochondrial and anti-redox cellular system alterations.
Therefore, it is undeniable that counteracting oxidative stress machinery is a major pharmacological
target in medicine/nephrology. As a consequence, in recent years several new naturally occurring
compounds, administered alone or integrated with classical therapies and an appropriate lifestyle,
have been proposed as therapeutic tools for CKD patients. In this paper, we reviewed the recent
literature regarding the “pioneering” in vivo testing of these agents and their inclusion in small
clinical trials performed in patients affected by CKD.
Keywords: oxidative stress; reactive oxygen species; chronic kidney disease; antioxidants; nephrology
1. Introduction
Oxidative stress, a biochemical imbalance between reactive oxygen species (ROS) production
and antioxidant defenses, has been reported as an important biochemical hallmark of several
human diseases.
In chronic kidney disease (CKD), this deregulated biochemical machinery has been associated
with disease progression and with the onset/development of severe systemic complications (mainly
atherosclerosis and other cardiovascular diseases), with a consequent remarkable impact on major
clinical outcomes [1–6].
Although present from the early stages of renal impairment, it appears severely enhanced with
advancing stages of CKD and the start of renal replacement therapy (hemodialysis or peritoneal
dialysis) [3].
Several biological factors are responsible for oxidative stress in this large population of patients,
but, as recently described, mitochondrial deregulation seems to have a primary role [7–9].
Mitochondria are organelles with a major role in generating energy for cellular metabolism by the
oxidative phosphorylation system (OXPHOS), and they are involved in several physiological cellular
functions (e.g., ion homeostasis, heme and steroid synthesis, calcium signaling, apoptosis [10–13]).
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During CKD mitochondria may undergo a profound deregulation that can induce functional alterations.
CKD is associated with a decline in mitochondrial content at the early stage of the disease [14].
In particular, during renal damage, continuous mitochondrial insults may activate a vicious
functional circle responsible for an overproduction of ROS which can induce mitochondrial DNA
mutations, damage the mitochondrial respiratory chain, alter membrane permeability, and influence
Ca2+ homeostasis and mitochondrial defense systems. Mitochondrial dysfunction and renal failure are
strictly connected: it has been demonstrated that the role of mitochondria in podocyte injury leads to
proteinuria [15,16] as well as epithelial to mesenchymal transition of tubular epithelial cells [17,18].
Moreover, uremic toxins impair OXPHOS in epithelial tubular cells [19].
Other biological factors contributing to oxidative stress in CKD are the enzymatic complex
NADPH oxidase and the xanthine oxidase pathway. NADPH oxidase catalyzes the transfer of electrons
to oxygen to produce superoxide anion (O2−) that is immediately converted to H2O2. These, in turn,
are precursors of other ROS that cause damages to proteins, lipids, and nucleic acids [20]. NADPH
oxidase-derived ROS are involved in cell signaling, ion channel activity, gene expression, and in the
direct killing of invading microbes in phagocytes. Its activity is upregulated in all stages of CKD and
in dialysis [21–23].
Xanthine oxidase catalyzes the oxidation of hypoxanthine to xanthine and xanthine to uric acid
together with ROS release. Xanthine oxidase activity is higher in CKD patients [24] and could be
an independent predictor of cardiovascular events in CKD and hemodialysis patients [25]. In this
context, allopurinol, the xanthine oxidase inhibitor acting as a competitive substrate for the enzyme,
decreases serum uric acid levels and its toxic effects [26]. Several studies have shown that allopurinol
treatment decreases C-reactive protein (CRP) levels, slows the progression of renal disease, decreases
the number of hospitalizations, and reduces cardiovascular risk [27–30]. However, since it is excreted
by urine, it requires individual dosage modification in CKD patients, and consequently may have
poor control over the serum concentration of uric acid [31,32]. In addition, systematic reviews have
highlighted that allopurinol could have only a partial therapeutic efficacy, and may also induce adverse
effects in CKD patients [33,34].
Febuxostat, an orally administered nonpurine selective inhibitor of xanthine oxidase with two
excretion pathways (urinary and fecal), was more effective in the reduction and maintenance of serum
urate levels <6.0 mg/dL compared to allopurinol in patients with renal impairment [35–37].
At the same time, antioxidant systems are defective in CKD [38–41], but we recently described that
nuclear factor erythroid 2-related factor 2 (NRF-2) and one of its target genes, superoxide dismutase
(SOD) 2, are upregulated in dialysis-treated patients, defining a possible antioxidant system able to
contrast ROS production.
Therefore, a worldwide interest is emerging in identifying and testing compounds able to
significantly counteract oxidative damage in CKD. In particular, natural compounds targeting
mitochondria, alone or combined with conventional therapies and lifestyle modifications, could
represent valuable tools to prevent this condition and, because of the low adverse effects, they could
be employed in patients undergoing both conservative and dialysis treatment [42].
These compounds are frequently included in the diet at biologically active concentrations and
represent essential elements of traditional medicine from several countries. Although effective and
relatively safety, they have been only partially investigated in nephrology and their efficacy in CKD is
still debated.
To this purpose, a large number of studies have begun to address this objective by employing
animal models and small clinical trials.
2. L-Carnitine
L-Carnitine (4-N-trimethylammonium-3-hydroxybutyric acid) is an amino acid-derived
compound obtained mostly through the diet, particularly from animal-derived foods. It is
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endogenously synthesized in the kidney and liver from lysine and methionine, with a daily rate
of 1.2 µmol/kg/day [43].
L-Carnitine acts as a transporter of long-chain fatty acids chains across the mitochondrial inner
membrane, through a series of reversible transesterification reactions catalyzed by the group of
carnitine acyltransferases. In these reactions, coenzyme A (CoA), bound to fatty acids, is substituted by
the hydroxyl group of carnitine, forming acyl-carnitine. This molecule is transported from the cytosol
to the inner mitochondrial matrix thanks to the combined activity of carnitine-acyl-carnitine translocase
and carnitine palmitoyltransferase I and II. Here, acyl-carnitine is converted again into acyl-CoA,
which can enter the β-oxidation and finally generate energy in the electron transport chain [44,45].
Carnitine is thus fundamental for mitochondrial and cellular physiological activity. It has been
demonstrated that its deficiency leads to (1) the accumulation of free fatty acids into cells; (2) impaired
export of the excess of organic acids, particularly in some of the secondary carnitine insufficiencies,
including hemodialysis; and (3) increased mitochondrial dysfunction and ROS production, secondary
to acetyl-CoA accumulation and multiple enzymatic inhibition [44,46].
Furthermore, carnitine acts as both a direct and indirect antioxidant by scavenging ROS, chelating
iron [47], increasing the expression and activity of antioxidant enzymes [48], and by inhibiting lipid
peroxidation and xanthine oxidase activity [49,50].
CKD is characterized by a reduced synthesis of L-carnitine, proportional to the decline of the
glomerular filtration rate (GFR). Nevertheless, its level is higher in CKD patients under conservative
therapy than in healthy individuals, probably through a compensatory effect of the liver [51].
On the other hand, CKD patients undergoing hemodialysis (HD) and peritoneal dialysis (PD)
show a reduction of free L-carnitine levels in plasma and muscle. This is due to several factors,
including loss during dialysis treatment, intestinal malabsorption, and the impaired synthetic capacity
of the kidney. In particular, Di Liberato et al. suggested a potential role of PD modality (CAPD) on
carnitine depletion and the possible advantage of carnitine-containing dialysis fluids [52].
Due to its antioxidant role, the oral administration of L-carnitine to HD patients resulted
in an increased glutathione (GSH) level, increased glutathione peroxidase activity, and a decreased
malondyaldeide (MDA) level [53,54]. Interestingly, several reports have suggested that its supplementation
might have a positive effect on the response to erythropoietin (EPO) in long-term hemodialysis
patients [55–58], but it did not modify EPO requirements in patients new to hemodialysis [59].
During the past few years, some federal agencies have suggested the use of L-carnitine in
HD. In 2003, the National Kidney Foundation developed a practice recommendation for the use of
L-carnitine in patients with dialysis-related carnitine disorders, most notably erythropoietin-resistant
anemia, intradialytic hypotension, cardiomyopathy, and fatigability [60]. However, KDOQI guidelines
state that there is not sufficient evidence to recommend the administration of L-carnitine to HD patients
with anemia [61].
Two important meta-analyses of the L-carnitine administration in HD patients were recently
published, with controversial results. Chen et al. concluded that L-carnitine administration decreases
serum low density lipoprotein (LDL) and CRP, while it fails to ameliorate EPO responsiveness and
anemia [62]. In contrast Yang et al. did not find any conclusive evidence of effectiveness against
inflammation, oxidative stress, anemia, nutrition, dyslipidemia, hyperparathyroidism, or quality of
life in HD patients undergoing L-carnitine administration. These contrasting results suggest that
additional long-term controlled randomized clinical trials are necessary to definitively understand the
clinical utility of carnitine administration in CKD patients [63].
3. Vitamin E
Vitamin E encompasses a group of eight chemically related molecules, comprising α, β, γ, δ
tocopherol, and the derived tocotrienols [64]. The most biologically active form is α-tocopherol [65].
The main sources of vitamin E are seed oils (wheat germ oil: 150 mg/mL, almond oil: 95 mg/mL, olive
oil: 15 mg/mL).
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α-Tocopherol maintains the integrity of long-chain polyunsaturated fatty acids in the membranes
of cells and thus preserves their bioactivity [66,67]. In particular, it protects lipid structures from
peroxidation and increases LDL resistance to oxidative modification [68,69], suggesting a potential
effect of vitamin E in the prevention of atherosclerosis [70,71].
Vitamin E is a powerful peroxyl radical scavenger that returns to its reduced state by reacting
with vitamin C (or other hydrogen donors) [72].
Moreover, it reduces the mitochondrial generation of hydrogen peroxide and it regulates the
expression of genes implicated in inflammation and fibrosis [73–76].
Although vitamin E therapy has been extensively studied in CKD patients, there is no consensus
about the benefit obtained from its administration.
The SPACE study evaluated the cardiovascular protective effects of orally administered, high
doses of vitamin E (800 IU/die) on HD patients with previous cardiovascular events, over a period
of 519 days. The treatment resulted in a 40% decline in both composite cardiovascular events and
myocardial infarction [77].
On the other hand, the administration of vitamin E (400 IU/day) to patients with mild to moderate
renal failure failed to obtain beneficial effects on cardiovascular outcomes in the Heart Outcomes
Prevention Evaluation (HOPE) study [78].
These contrasting results may be partially due to differences in the enrollment criteria (e.g., the
SPACE trial included patients with higher cardiovascular risk, and participants were treated with
a higher dose of vitamin E); moreover, most participants in the SPACE trial (43.3% of the vitamin
E group) also consumed vitamin C. Finally, the SPACE study enrolled a smaller sample (196 HD
patients) compared with other trials, which resulted in large confidence intervals based on a broad
composite end-point.
More recent studies have shown the positive effect of vitamin E administration before coronary
procedures in the prevention of contrast-induced acute kidney injury in patients with CKD undergoing
elective coronary procedures [79,80].
Additionally, long-term use of vitamin E-coated HD filters improved oxidative stress,
inflammatory markers, and hemoglobin levels, and reduced Erythropoiesis-Stimulating Agents (ESA)
requirement without affecting dialysis adequacy [81–87].
Vitamin E combined with Pravastatin and homocysteine-lowering therapy was evaluated against
vascular stiffness progression over 18 months in patients with mild to moderate CKD. This treatment
resulted in significant improvement of vascular compliance and distensibility, decrement in common
carotid intima-media thickness, and increase in brachial artery flow-mediated dilatation; however, the
effect of other confounding variables was unclear [88,89].
It is noteworthy that vitamin E could have also a pro-oxidant action under special conditions that
can be encountered in HD patients [90,91]. In fact, oral α-tocopherol administration (500 mg/day) for
1 year to HD patients caused reduced SOD activity and total antioxidant status [91]. This could be due to
the low level of other antioxidants necessary to restore the reduced form of vitamin E (e.g., vitamin C) [92].
Based on research studies, vitamin E supplementation could be a potential valuable adjuvant
therapy to contrast oxidative stress and lower lipid peroxidation in CKD and HD patients. Still,
because of its adverse effects [93], its clinical employment in nephrology needs to be better defined.
4. Vitamin C
Vitamin C (ascorbic acid) is a water-soluble essential antioxidant obtained from citrus fruits and
some green vegetables such as broccoli and spinach [94]. Its recommended daily dose is approximately
90 mg in adult men and 75 mg in adult women [95].
Vitamin C prevents oxidative damage by scavenging ROS and reactive nitrogen species [96].
Moreover, it shows an anti-apoptotic activity by maintaining the mitochondrial membrane potential
and protecting mitochondrial DNA from oxidant insults [97–100].
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It has been demonstrated that a reduction in both the total vitamin C concentration and the active
form (ascorbate) is probably caused by the limited intake of potassium-rich foods in CKD patients
in conservative treatment, and by the loss during HD treatment. Another possible explanation is an
impairment of enzymatic or non-enzymatic recycling of ascorbate from dehydroascorbate (the oxidized
form of vitamin C), since the recycling is largely GSH-dependent [101] and dialysis patients have
a marked GSH deficiency [102,103]. The low vitamin C plasma levels in CKD patients has been, then,
associated with an increased risk for fatal and nonfatal major adverse cardiovascular events [104,105].
To avoid this condition, currently oral ascorbate (1–1.5 g/week) or parenteral ascorbate
(300 mg/dialysis session) are suggested to balance subclinical deficiency [103].
Poly-vitamin supplementation, including vitamin C (250 mg/day), for eight weeks to HD patients
did not induce any change in inflammation, malnutrition, or oxidative stress markers [106].
Moreover, in a double-blind randomized clinical trial on CKD patients (stage IV–V and HD),
vitamin C (250 mg, three times a week) failed to demonstrate a real clinical benefit when evaluated
against uremic symptoms and cardiovascular stability [107].
Conversely, several studies showed advantages of vitamin C administration. In a cross-over study,
patients treated for three months with vitamin C (200 mg/day) showed decreased CRP levels and
increased serum prealbumin concentration as marker of malnutrition [108]. Interestingly, the use of
vitamin E-coated dialysis membranes significantly reduced oxidative stress, avoided a reduction of
erythrocyte reductases activity, and decreased the level of proinflammatory cytokines [81]. Moreover,
other studies reported that this vitamin improved the response to ESA with a significant enhancement
of hemoglobin levels and transferrin saturation [109,110]. At the moment, despite encouraging results
from clinical research studies, the use of vitamin C is still debated in nephrology.
5. Coenzyme Q10
Coenzyme Q10 (CoQ10) is a high lipophilic molecule diffuse in eukaryotic cells that is mostly
concentrated in mitochondria, as component of the mitochondrial respiratory chain where it transports
electrons from complex I/II to complex III [111].
It is synthesized in the human body and is assumed with food (animal muscle and liver, blue fish,
soy beans, and olive oil) with an estimated daily intake of 3–6 mg [112].
Due to its abundant distribution and intra-membranous localization, CoQ10 prevents membrane
lipid peroxidation since hydroxyl and superoxide radicals generated in the membrane during electron
transport chain would otherwise rapidly react with neighboring lipid and protein molecules [113,114].
CoQ10 regenerates vitamin E from the α-tocopheroxyl radical and prevents the oxidation of
nucleic acids, particularly of mitochondrial DNA [113]. Additionally, it inhibits mitochondria-
dependent apoptosis by preventing permeability transition pore opening and mitochondrial membrane
potential depolarization [111,115]. Moreover, increased mitochondrial CoQ10 content results in
a general improvement of bioenergetic parameters, such as oxygen consumption, ATP content,
mitochondrial potential, and protein synthesis [116].
As a consequence, CoQ10 has been studied in clinical settings in order to prevent atherosclerosis,
aging, and the progression of chronic diseases such as CKD.
In CKD patients, it an inverse relationship between CoQ10 and renal function has been
reported [117,118].
An interesting correlation was also demonstrated between reduced CoQ10 levels and epicardial
fat tissue (EFT) in HD patients [119]. EFT is the visceral adipose tissue surrounding the subepicardial
coronary vessels. It is an active source of proinflammatory factors [120–122], and, in greater amounts,
has recently been related to a higher risk for atherosclerosis and heart disease in PD and HD
patients [123,124]. Thus, increased EFT in HD patients could cause the consumption of CoQ10
as an antioxidant molecule, and its supplementation was hypothesized able to correct this imbalance,
reducing cardiovascular risk.
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In a recent trial involving patients in maintenance HD, oral CoQ10 (200 mg/day) supplementation
did not induce changes in exercise performance and in the blood level of oxidative system markers
compared with a placebo [125].
As with other similar compounds, at present, there is no a clear evidence that justifies the “day by
day” clinical employment of CoQ10 in CKD patients in both conservative and dialysis treatment.
6. α-Lipoic Acid
α-Lipoic acid (ALA) is a disulfide compound that acts as a coenzyme in pyruvate dehydrogenase
and α-ketoglutarate dehydrogenase mitochondrial reactions [126]. Typical dietary sources of ALA are
muscle meats, heart, kidney, and liver, and to a lesser degree, fruits and vegetables [127].
ALA and its reduced form, dihydrolipoic acid, have several antioxidant, anti-inflammatory, and
metabolic activities.
ALA exerts direct antioxidant activity by chelating Cu2+, Zn2+, and Fe2+ [128,129], and it recycles
other cellular antioxidants including CoQ10, vitamins C and E, and GSH. It also regulates the
expression of numerous genes trough the inhibition of NFkB [130] and the induction of NRF2 [131].
As a modulator of peroxisome proliferator-activated receptor (PPAR)-α and -γ expression, ALA
is implied in the regulation of glucose and lipid metabolism [131].
Moreover, it inhibits vascular calcification and vascular smooth muscle cell apoptosis by
preserving mitochondrial functions and activating the PI3K/Akt pathway [132].
In a model of diabetic nephropathy, it reduced the progression of renal damage, glomerular
mesangial matrix expansion, and glomerulosclerosis by restoring GSH, reducing MDA levels, and
protecting mitochondrial function [133,134].
However, ALA supplementation in hemodialyzed patients showed uncertain results. A daily
dose of 600 mg for eight weeks caused a reduction of CRP levels, without showing effects on MDA,
total antioxidant status, total cholesterol, triglyceride, high-density lipoprotein cholesterol, or LDL
levels [135]. Contrarily, in other studies, ALA combined with mixed tocopherols did not modify the
level of several biomarkers of inflammation and oxidative stress [136–139].
Further studies, probably using mixed antioxidants and longer courses of treatment, could be
useful to demonstrate the clinical utility of ALA supplementation in this patient population.
7. Selenium
Selenium is a non-metal element essential for human physiology, since it acts as a cofactor for
several enzymes with an antioxidant role (glutathione peroxidase, thioredoxin reductase) [140]. It is
obtained from meat, seafood, grains, cereals, fish (tuna and mackerel), and plants (garlic, onions, and
broccoli), but the best source of selenium is Brazil nuts [141].
Several reports have demonstrated a selenium deficiency in CKD and dialyzed patients [142–145].
In patients with CKD, selenium supplementation increased the glutathione peroxidase
activity [146], but unfortunately, this positive effect was detectable only if this agent was administered
in the early stages of renal impairment [147].
Selenium supplementation (200 µg) for 12 weeks prevents the damage of DNA [148] and improved
MDA levels [149], without showing any significant effects on inflammatory and thyroid functional
biomarkers [150].
Moreover, 600µg sodium selenide co-administered with 400 IU vitamin E before an HD session
offsets the serum MDA increment induced by iron infusion [151].
At the moment, there is no indication to the use of selenium in CKD and additional, larger clinical
studies are necessary to define its future potential employment in this clinical setting.
8. Green Tea
Green tea is composed of several polyphenolic compounds, but (−)-Epigallocatechin-3-gallate
(EGCG) is the most abundant and effective as an antioxidant [152]. In fact, it is implicated in ROS
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scavenging, the inhibition of lipid peroxidation, and the chelation of metal ions such as copper (II) and
iron (III) [153–156].
Recently these protective properties have become of interest specifically in kidney diseases, and
EGCG has been tested in several animal models of glomerulonephritis [157]. Treatment with EGCG
reduced proteinuria and serum creatinine, and it determined a marked improvement in several renal
histological features. These effects seemed to be mediated by the direct and indirect effects of these
agents on the redox cellular/biological system and the immune-inflammatory pathway [158–160].
In particular, EGCG increased renal NRF2 and glutathione peroxidase activity; reduced renal oxidative
stress, NF-κB activation, and NLRP3 mRNA/protein expression as well as protein levels of mature
caspase-1, IL-1β, and IL-18; and enhanced splenic regulatory T cell activity. EGCG-treated mice also
showed a reduction in p-Akt, p-JNK, p-ERK1/2, and p-P38 as well as the restoration of peroxisome
proliferator-activated receptor (PPAR)γ and sirtuin-1 (SIRT1) levels [158–160].
In streptozotocin-induced diabetic nephropathy, EGCG administration for 50 days improved renal
function as well as reduced renal AGE accumulation, lipid peroxidation, and fibronectin levels [161].
In animal models of unilateral urethral obstruction, EGCG caused the upregulation and
nuclear translocation of NRF2, with the consequent enhancement of antioxidant enzymes such as
γ-glutamylcysteine synthetase [162].
EGCG significantly reduced uremic toxins, such as methylguanidine levels, in a dose-dependent
manner in rats with adenine-induced renal failure [163].
In an ischemia reperfusion injury model, EGCG treatment, via monocyte chemoattractant
protein-1 (MCP-1) and transforming growth factor (TGF-β) downregulation and heme oxygenase 1
(HO-1) augmentation, protected the kidneys from a massive infiltration of macrophages [164] and the
development of chronic renal alterations.
It must be noted, however, that all of the abovementioned studies are speculative and no large
clinical trials have been published in nephrology.
9. Resveratrol
Resveratrol (3,5,4′-trihydroxystilbene) is a naturally occurring polyphenolic compound present
in more than 70 species of plants, with the greatest amount found in grapes, berries, red wine, and
peanuts [165].
Resveratrol can directly scavenge ROS and modulate the expression and activity of antioxidant
enzymes such as SOD, glutathione peroxidase, and catalase, through transcriptional regulation
via NRF-2, activator protein 1 (AP-1), forkhead box O (FOXO), and SP-1 [166,167]. Moreover,
it is an activator of SIRT1, an NAD+-dependent deacetylase of histones, which results in reduced
transcriptional activity. SIRT1 plays a key role in responding to nutritional and environmental
perturbations such as fasting, calorie restriction, starvation, and nutrient deprivation, as well as
in oxidative stress conditions [168,169]. SIRT1 activates peroxisome proliferator-activated receptor
gamma coactivator 1-α (PGC-1α) and attenuates sterol-regulatory-element-binding protein (SREBP)
activity, resulting in increased fatty acid oxidation, reduced lipogenesis and cholesterolgenesis, and
improved glucose homeostasis and mitochondrial function [170,171]. Moreover, it deacetylates
FOXO, p53, hypoxia-inducible factor (HIF)-1α, and NFkB, mediating antiapoptotic, antioxidative, and
anti-inflammatory effects [172,173].
Due to its cytoprotective effects, resveratrol has been largely tested in animal models of chronic
renal diseases. In streptozotocin-induced diabetic rats, resveratrol (5 or 10 mg/kg administered orally)
improved renal dysfunction and oxidative stress, and attenuated cytokine levels [174,175].
Resveratrol, then, seemed to prevent in vitro high glucose-induced mesangial cell proliferation
and fibronectin expression by inhibiting JNK and NF-κB, as well as NADPH oxidase activity and ROS
production [176]. These results were in line with more recent studies that demonstrated a positive
effect of this agent in podocytes of db/db mice through the activation of the autophagic pathway [177].
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Resveratrol, through its antioxidant mechanisms and the deacetylation of Smad3, directly prevents
EMT and renal fibrosis [176,178–181], and inhibits CKD-induced skeletal muscle atrophy mediated by
NF-κB [182].
Moreover, by enhancing the AMPK/SIRT-1/PGC-1α axis [183] this agent could attenuate
mitochondrial dysfunction and aldosterone-induced podocyte injury [184].
In other animal models of AKI (cisplatin nephropathy, ischemia-reperfusion, and sepsis-related
acute renal damages), resveratrol demonstrated a considerable renal protective effect by normalizing
Nrf2 renal expression, enhancing antioxidant factors expression (HO-1, GST), and reducing
inflammatory mediators (TNF-α, IL-6) [185–187].
Unfortunately, although resveratrol has demonstrated low adverse effects, no study has been
developed to evaluate its efficacy in CKD patients, probably because its low bioavailability [188]. In the
future, the employment of this agent in combination with other compounds could probably permit its
use to counteract the progression to end-stage renal disease.
10. Curcumin
Curcumin is the active element of curcuma longa (or turmeric), a perennial herbaceous plant
member of the ginger family (Zingiberaceae), prevalent in India, China, and Southeast Asia [189].
In Ayurvedic and Chinese medicine, curcumin is used as anti-inflammatory, antioxidant,
antibacterial, and antimicrobial reagent, as well as to treat chronic diseases [190–194].
Its antioxidant properties are due to both a direct scavenger activity and the upregulation of
antioxidant and cytoprotective genes. Curcumin is able to directly scavenge superoxide anions,
hydroxyl radicals, H2O2, singlet oxygen, nitric oxide, and peroxynitrite [195–198], probably by means
of phenolic groups in its molecular structure. Curcumin also has an indirect antioxidant ability
mediated by the induction of the expression of cytoprotective enzymes such as SOD, catalase [199],
glutathione reductase, HO-1 [200], glutathione S-transferase, NAD(P)H:quinone oxidoreductase 1 [201],
and γ-glutamylcysteine ligase [202].
Several studies have reported the reno-protective effects of curcumin in a mouse model of
diabetic nephropathy. Administration of curcumin (15–150 mg/kg/day for two to eight weeks)
ameliorated renal function through the upregulation of antioxidant enzymes, inhibition of NADPH
oxidase and NFkB, and it reduced macrophages infiltration and proinflammatory cytokines together
with antifibrotic activities [203–207].
Likewise, in an animal model of CKD, curcumin significantly reversed proteinuria, hypertension,
interstitial fibrosis, fibrotic glomeruli, tubular atrophy, and mesangial expansion [208–213]. Interestingly,
the preservation of mitochondrial dynamics, bioenergetics, and oxidative stress has been recently
demonstrated in a rat model of CKD, which may be associated with ameliorated renal function [214].
Moreover, curcumin improved structural and functional manifestations of cardiac injury
associated with renal failure, in part through the inhibition of NLRP3 inflammasome and the
preservation of mitochondrial function [215–217].
Khajehdehi et al. showed that an oral supplementation of 500 mg turmeric (of which 22.1 mg was
the active ingredient curcumin) for three months has strong renal protective effects in lupus nephritis
and type 2 diabetic nephropathies [218,219].
However, although it is a promising agent for the treatment of chronic glomerulopathies and
tubular renal dysfunctions, at the moment, the clinical evidences are not adequate to justify a large
utilization of this compound in our nephrology patients.
11. Omega-3 Polyunsaturated Fatty Acids
Omega-3 polyunsaturated fatty acids (omega-3 PUFAs) are a class of essential long-chain fatty
acids obtained primarily from dietary sources.
The two most bioactive and extensively studied omega-3 fatty acids are eicosapentaenoic acid
(EPA) and docosahexaenoic acid (DHA) [220].
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Omega-3 PUFAs exert anti-inflammatory activity by modifying the expression of adhesion
molecules, chemotactic factors, and proinflammatory cytokines (TNF-α, IL-1β, and IL-6) [221–224].
Another mechanism is the prevention of the conversion of arachidonic acid into proinflammatory
eicosanoids such as prostaglandin (PG) and leukotriene (LT) [225], and serving as an alternative
substrate to produce less potent 5-series LTs, 3-series PGs, and thromboxanes [226]. In addition,
omega-3 PUFA-derived resolvins such as resolvin E1 (RvE1) and D-series resolvins and protectin D1
from DHA have potent anti-inflammatory actions [227,228].
These compounds maintain the structure and function of cell and organelle membranes [229],
participating in membrane fluidity, ion channels transport (sodium, potassium, and calcium) [230],
and mitochondrial biogenesis [231].
In addition to anti-inflammatory properties, omega-3 fatty acids also have antioxidant effects.
They enhance endogenous antioxidant defense systems such as GSH through the increased
activity of γ-glutamyl-cysteinyl ligase, glutathione reductase, and glutathione S-transferase [232], and
compete with arachidonic acid at COX2 and xanthine oxidase sites, reducing ROS synthesis [233].
In animal models of CKD, EPA and DHA supplementation reduce inflammation, fibrosis, and
oxidative stress [234–236].
In CKD and dialysis patients, the administration of omega-3 PUFAs can reduce inflammation
associated with CKD progression through the upregulation of E- and D-series resolvins [237], together
with the reduced level of endothelial chemokines, RANTES, and MCP-1 [238].
At the same time, recent studies suggest a benefit of omega-3 PUFAs supplementation in
ameliorating uremic symptoms (particularly pruritus) [239] and reducing hypertension [240,241].
In a randomized controlled clinical trial on 78 patients affected by IgA nephropathy, PUFAs
associated with renin-angiotensin system blockers were more effective than renin-angiotensin system
blockers alone in reducing proteinuria. Unfortunately, the small number of patients, the short time of
observation (six months) and the single-center nature of the study limits the power of these conclusions [242].
Because of the few strong evidences of its benefit in CKD, additional studies are warranted to
assess the real efficacy of these agents in slowing the progression of renal failure and to establish the
formal intake recommendations and dosing in the CKD patient population (particularly in dialysis).
12. Conclusions
CKD is associated with enhanced oxidative stress that is a well-known risk factor for the
onset/development of severe systemic complications and cardiovascular diseases. Several studies
report a higher level of oxidative stress markers together with reduced antioxidants in pre-dialysis
patients. This condition is exacerbated during the progression of renal failure and in renal replacement
therapy. Several biological mechanisms contribute to oxidative stress, including mitochondrial activity,
xanthine oxidase, and NADPH oxidase. Thus, in recent years the administration of antioxidants,
both food-derived and through drugs with additional antioxidant effects, have demonstrated positive
effects. Many of these compounds have direct ROS scavenger properties due to their molecular
structure (L-carnitine, vitamin E, vitamin C, α-lipoic acid, green tea, resveratrol, curcumin), others also
have indirect antioxidant effects mediated by the upregulation of antioxidant enzymes (L-carnitine,
green tea, α-lipoic acid, resveratrol, curcumin) or by additional anti-inflammatory properties (vitamin
E, resveratrol, curcumin, omega-3).
However, the great limit of most of these studies is the low sample size and short-term follow-up.
As a consequence, none of these molecules have been introduced into usual clinical practice. Therefore,
future prospective and comparative studies analyzing the co-administration of different antioxidants
with long-term follow-up are warranted.
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